- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CYBN
Recent news which mentions CYBN
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
September 26, 2023
From Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
September 26, 2023
From Benzinga
From Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
September 20, 2023
From Benzinga
Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
September 19, 2023
From Benzinga
From InvestorPlace
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
September 18, 2023
From Benzinga
The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023
September 14, 2023
From InvestorPlace
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
From Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
From Benzinga
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
September 05, 2023
From Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
From Benzinga
From Benzinga
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M
August 29, 2023
From Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
From Benzinga
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
August 28, 2023
From Benzinga
Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M
August 24, 2023
Tickers
CYBN
From Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
From Benzinga
Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library
August 16, 2023
Tickers
CYBN
From Benzinga
Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic
August 14, 2023
Tickers
CYBN
From Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
From Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
From Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 01, 2023
From Benzinga
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
August 01, 2023
From Benzinga
US Stocks Mixed; Pfizer Earnings Beat Views
August 01, 2023
From Benzinga
Why TETRA Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
August 01, 2023
From Benzinga
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.